Cost-effectiveness of implantable cardioverter-defibrillators in a MADIT-II population
Sanders GD, Hlatky MA, Owens DK
Record ID 32004000236
English
Authors' objectives:
The Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) randomized clinical trial demonstrated that implantable cardioverter-defibrillators (ICDs) improve survival in post-myocardial infarction (MI) patients with low ejection fraction. This cost-effectiveness analysis compares ICD implantation with conventional medical management in the population represented by MADIT-II.
Authors' recommendations:
Although previous randomized trials have reported significant reductions in total mortality with ICD implantation, these trials represent heterogeneous populations and outcomes and mostly include patients with documented arrhythmic events. MADIT-II did not require such a previous event, and it is believed that the efficacy of the ICD in this population may greatly broaden the number of eligible patients. Several clinical trials of prophylactic ICD implantation in patients similar to the MADIT-II population however are still ongoing. Once the results of these studies are available, a more comprehensive analysis of prophylactic ICD implantation will be feasible.
Authors' methods:
Cost study
Details
Project Status:
Completed
URL for project:
http://www.bcbs.com/blueresources/tec/contact-tec.html
Year Published:
2004
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Costs and Cost Analysis
- Defibrillators, Implantable
- Myocardial Infarction
Contact
Organisation Name:
BlueCross BlueShield Association
Contact Address:
BlueCross BlueShield Association, Technology Evaluation Center, 225 North Michigan Ave, Chicago, Illinois, USA. Tel: 888 832 4321
Contact Name:
tec@bcbsa.com
Contact Email:
tec@bcbsa.com
Copyright:
BlueCross BlueShield Association (BCBS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.